CLINICAL TRIALS PROFILE FOR EPETRABOROLE
✉ Email this page to a colleague
Clinical Trials for Epetraborole
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT04892641 ↗ | Phase 1 Study of Epetraborole Tablets | Recruiting | AN2 Therapeutics, Inc | Phase 1 | This is a Phase 1b double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and food effect of epetraborole tablets administered to healthy adult subjects for up to 28 days. |
| NCT05283746 ↗ | A Phase 1 of Epetraborole Tablets | Recruiting | AN2 Therapeutics, Inc | Phase 1 | This is a Phase 1 study to evaluate the pharmacokinetics (PK), safety and tolerability of epetraborole tablets in adult subjects with normal renal function, subjects with various degrees of renal impairment, and subjects with end-stage renal disease (ESRD) receiving intermittent hemodialysis (IHD) therapy. |
| NCT05327803 ↗ | Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease | Not yet recruiting | AN2 Therapeutics, Inc | Phase 2/Phase 3 | This pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Epetraborole
Condition Name
Clinical Trial Locations for Epetraborole
Trials by Country
Clinical Trial Progress for Epetraborole
Clinical Trial Phase
Clinical Trial Sponsors for Epetraborole
Sponsor Name
